Ralph Boccia is an Oncology physician affiliated with Center for Cancer and Blood Disorders. OpenAlex indexes 275 publications with 7,227 citations (h-index 38); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Rockledge Dr
Suite 660
Bethesda, MD 208171809
Telephone
301-571-0019Provider last certified this registry record 3 Jan 2023.
Clinical trials
- Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
Sponsor: MediMergent, LLC
- Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Sponsor: Spectrum Pharmaceuticals, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
119 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Fennec Pharmaceuticals, Inc.Program year202522 payments$53,993openpaymentsdata.cms.gov ↗
- Aadi Bioscience, Inc.Program year20251 payment$33,500openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202537 payments$31,845openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
74.8%Erythropoiesis-stimulating Agent62.1%Darbepoetin alfa100%Part B, office-administered≥93 patientsIron, parenteral preparations12.6%Ferric derisomaltose98%Iron dextran2%Part B, office-administered≥174 patients+ 3 more classes in this area
Cancer & immunology
11%CD38-directed Cytolytic Antibody10.8%Daratumumab100%Part B, office-administered≥11 patientsKinase inhibitor0.1%Calquence30%Brukinsa27%Jakafi23%Ibrance8%Tasigna7%Sprycel6%Part D<11 patients+ 8 more classes in this area
Anti-infectives
9.5%Human Immunoglobulin G9.5%Immune globulin100%Part B, office-administered≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
British Journal of Haematology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Christopher Silliman, MD
Center for Cancer and Blood Disorders
Joanne Hilden, MD
Center for Cancer and Blood Disorders
Girish Dhall, MD
Center for Cancer and Blood Disorders
Katherine Tarlock, MD
Center for Cancer and Blood Disorders
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”